UA106209C2 - Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid - Google Patents
Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acidInfo
- Publication number
- UA106209C2 UA106209C2 UAA201103353A UAA201103353A UA106209C2 UA 106209 C2 UA106209 C2 UA 106209C2 UA A201103353 A UAA201103353 A UA A201103353A UA A201103353 A UAA201103353 A UA A201103353A UA 106209 C2 UA106209 C2 UA 106209C2
- Authority
- UA
- Ukraine
- Prior art keywords
- choline cocrystal
- phenylpropenylidene
- thioxo
- oxo
- methyl
- Prior art date
Links
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 title abstract 5
- 229960001231 choline Drugs 0.000 title abstract 5
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 title 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 206010020365 Homocystinuria Diseases 0.000 abstract 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 abstract 1
- 150000001323 aldoses Chemical class 0.000 abstract 1
- 230000005961 cardioprotection Effects 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение касается нового водородного двухкислотного сокристалла холина 5-[(1Z,2Е)- 3-фенилпропенилиден]- 3-тиазолидинуксусной кислоты.В документе представлена информация по получению и описание нового сокристалла холина согласно разным вариантам изобретения.Изобретение касается фармацевтических соединений, содержащих новый сокристалл холина, и связанно с терапевтическим применением нового сокристалла холина для лечения и профилактики разных заболеваний, включая лечение и профилактику осложнений диабета, лечение и профилактику гомоцистинурии, связанной с уменьшением уровней гомоцистеина в сыворотке крови, ингибирование альдозоредуктазы, а также создание кардиопротекторного эффекта у пациентов без диабета.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9490408P | 2008-09-06 | 2008-09-06 | |
PCT/US2009/055868 WO2010028132A2 (en) | 2008-09-06 | 2009-09-03 | Novel choline cocrystal of epalrestat |
Publications (1)
Publication Number | Publication Date |
---|---|
UA106209C2 true UA106209C2 (en) | 2014-08-11 |
Family
ID=41797847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201103353A UA106209C2 (en) | 2008-09-06 | 2009-09-03 | Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid |
Country Status (17)
Country | Link |
---|---|
US (3) | US8906948B2 (ru) |
EP (1) | EP2326632B8 (ru) |
CN (1) | CN102216281B (ru) |
AU (1) | AU2009288037B2 (ru) |
CA (1) | CA2738231C (ru) |
CY (1) | CY1119752T1 (ru) |
DK (1) | DK2326632T3 (ru) |
EA (2) | EA016904B1 (ru) |
ES (1) | ES2639019T3 (ru) |
GB (1) | GB2476202B (ru) |
HU (1) | HUE034456T2 (ru) |
LT (1) | LT2326632T (ru) |
PL (1) | PL2326632T3 (ru) |
PT (1) | PT2326632T (ru) |
SI (1) | SI2326632T1 (ru) |
UA (1) | UA106209C2 (ru) |
WO (1) | WO2010028132A2 (ru) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8697735B2 (en) | 2008-07-25 | 2014-04-15 | Bionevia Pharmaceuticals, Inc. | Solid forms of epalrestat |
DK2326632T3 (en) | 2008-09-06 | 2017-09-18 | Bionevia Pharmaceuticals Inc | New choline crystal of epalrestate |
EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
ES2555927T3 (es) * | 2011-01-20 | 2016-01-11 | Bionevia Pharmaceuticals Inc. | Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas |
ITMI20120586A1 (it) | 2012-04-11 | 2013-10-12 | Milano Politecnico | Co-cristalli di 3-iodiopropinil butilcarbammato |
CN103951634B (zh) * | 2014-05-07 | 2016-06-08 | 浙江东亚药业股份有限公司 | 一种依帕司他结晶盐水合物和羟基哌啶共晶物及其制备方法和应用 |
US9975066B2 (en) * | 2014-05-27 | 2018-05-22 | Artificial Cell Technologies, Inc. | Automated layer by layer construction of multilayer coated cores by TFF |
BR112021019596A2 (pt) | 2019-04-01 | 2021-11-30 | Applied Therapeutics Inc | Inibidores de aldose redutase |
KR20220025713A (ko) * | 2019-05-07 | 2022-03-03 | 유니버시티 오브 마이애미 | 유전성 신경병증 및 연관 장애의 치료 및 검출 |
CN113354596B (zh) * | 2021-06-01 | 2022-11-29 | 天津大学 | 依帕司他-二甲双胍盐丙酮溶剂化物及制备方法和应用 |
CN113277962B (zh) * | 2021-06-01 | 2023-02-07 | 天津大学 | 依帕司他-二甲双胍盐水合物及其制备方法和应用 |
CN113336718B (zh) * | 2021-06-01 | 2023-02-28 | 天津大学 | 依帕司他-二甲双胍盐及其制备方法和应用 |
CN113292511B (zh) * | 2021-06-01 | 2022-11-25 | 天津大学 | 依帕司他-二甲双胍盐乙醇水双溶剂化物及制备方法和应用 |
CN115947699B (zh) * | 2023-01-16 | 2024-01-19 | 威海海洋职业学院 | 以烟酰胺为前驱体的依帕司他共晶及其制备方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1247067A (en) | 1968-02-16 | 1971-09-22 | Fujisawa Pharmaceutical Co | Tricyclic enol ether compounds and the preparation thereof |
JPS5740478A (en) | 1980-08-22 | 1982-03-06 | Ono Pharmaceut Co Ltd | Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative |
JPS5852220A (ja) | 1981-09-24 | 1983-03-28 | Fujisawa Pharmaceut Co Ltd | 血清尿酸値低下剤 |
JPS6251955A (ja) | 1985-08-22 | 1987-03-06 | Sansei Seiyaku Kk | 飼料組成物 |
US5145679A (en) * | 1989-10-05 | 1992-09-08 | Hinson Joan B | Topical emollient for prevention and treatment of circulatory induced lesions |
GB9526264D0 (en) | 1995-12-21 | 1996-02-21 | Knoll Ag | Medical treatment |
WO1997035584A1 (en) | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating pain |
US6696407B1 (en) | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
US20020068740A1 (en) | 1999-12-07 | 2002-06-06 | Mylari Banavara L. | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
KR20030059287A (ko) * | 2000-11-30 | 2003-07-07 | 화이자 프로덕츠 인코포레이티드 | Gaba 작용제 및 알도스 리덕타제 억제제의 혼합물 |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
JP3547010B1 (ja) * | 2002-12-27 | 2004-07-28 | 小野薬品工業株式会社 | 5−[(1z,2e)−2−メチル−3−フェニル−2−プロペニリデン]−4−オキソ−2−チオキソ−3−チアゾリジン酢酸の結晶の製造方法およびその製剤 |
JP5069905B2 (ja) * | 2003-01-21 | 2012-11-07 | アプテュイト (ウエスト ラファイエット)、エルエルシー | 新規な共結晶化 |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
CA2548281C (en) * | 2003-12-09 | 2013-11-12 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
JP2005298424A (ja) * | 2004-04-13 | 2005-10-27 | Sawai Pharmaceutical Co Ltd | エパルレスタット結晶の製造方法 |
JP4892821B2 (ja) | 2004-09-30 | 2012-03-07 | 大日本印刷株式会社 | エパルレスタット製造法 |
JP4892915B2 (ja) * | 2005-10-04 | 2012-03-07 | 大日本印刷株式会社 | エパルレスタット製造法 |
US20110275695A1 (en) | 2008-06-13 | 2011-11-10 | Bionevia Pharmaceuticals, Inc. | Crystalline forms of zotepine hydrochloride |
WO2010011922A2 (en) | 2008-07-25 | 2010-01-28 | Bionevia Pharmaceuticals, Inc. | Novel crystalline salts of epalrestat |
US8697735B2 (en) | 2008-07-25 | 2014-04-15 | Bionevia Pharmaceuticals, Inc. | Solid forms of epalrestat |
WO2010011926A2 (en) | 2008-07-25 | 2010-01-28 | Bionevia Pharmaceuticals, Inc. | A novel betaine cocrystal of epalrestat |
DK2326632T3 (en) | 2008-09-06 | 2017-09-18 | Bionevia Pharmaceuticals Inc | New choline crystal of epalrestate |
-
2009
- 2009-09-03 DK DK09812208.8T patent/DK2326632T3/en active
- 2009-09-03 PT PT98122088T patent/PT2326632T/pt unknown
- 2009-09-03 CA CA2738231A patent/CA2738231C/en not_active Expired - Fee Related
- 2009-09-03 ES ES09812208.8T patent/ES2639019T3/es active Active
- 2009-09-03 AU AU2009288037A patent/AU2009288037B2/en not_active Ceased
- 2009-09-03 HU HUE09812208A patent/HUE034456T2/en unknown
- 2009-09-03 EP EP09812208.8A patent/EP2326632B8/en not_active Not-in-force
- 2009-09-03 US US13/062,644 patent/US8906948B2/en active Active
- 2009-09-03 PL PL09812208T patent/PL2326632T3/pl unknown
- 2009-09-03 GB GB1105528.2A patent/GB2476202B/en not_active Expired - Fee Related
- 2009-09-03 EA EA201100245A patent/EA016904B1/ru not_active IP Right Cessation
- 2009-09-03 UA UAA201103353A patent/UA106209C2/ru unknown
- 2009-09-03 WO PCT/US2009/055868 patent/WO2010028132A2/en active Application Filing
- 2009-09-03 SI SI200931721T patent/SI2326632T1/sl unknown
- 2009-09-03 LT LTEP09812208.8T patent/LT2326632T/lt unknown
- 2009-09-03 EA EA201200489A patent/EA023435B1/ru not_active IP Right Cessation
- 2009-09-03 CN CN200980143667.4A patent/CN102216281B/zh not_active Expired - Fee Related
-
2014
- 2014-11-04 US US14/532,517 patent/US9611234B2/en active Active
-
2017
- 2017-03-03 US US15/449,723 patent/US10464912B2/en not_active Expired - Fee Related
- 2017-08-30 CY CY20171100917T patent/CY1119752T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
GB2476202A (en) | 2011-06-15 |
US8906948B2 (en) | 2014-12-09 |
CA2738231C (en) | 2015-04-07 |
GB201105528D0 (en) | 2011-05-18 |
HUE034456T2 (en) | 2018-02-28 |
CA2738231A1 (en) | 2010-03-11 |
EA201200489A1 (ru) | 2013-01-30 |
EP2326632A2 (en) | 2011-06-01 |
PT2326632T (pt) | 2017-09-05 |
US9611234B2 (en) | 2017-04-04 |
EP2326632B1 (en) | 2017-05-31 |
US20170174643A1 (en) | 2017-06-22 |
DK2326632T3 (en) | 2017-09-18 |
WO2010028132A2 (en) | 2010-03-11 |
US20150057319A1 (en) | 2015-02-26 |
CN102216281B (zh) | 2014-11-05 |
WO2010028132A3 (en) | 2010-06-17 |
EP2326632A4 (en) | 2012-05-30 |
SI2326632T1 (sl) | 2017-11-30 |
AU2009288037A1 (en) | 2010-03-11 |
LT2326632T (lt) | 2017-09-25 |
ES2639019T3 (es) | 2017-10-25 |
EP2326632B8 (en) | 2017-08-09 |
EA016904B1 (ru) | 2012-08-30 |
CN102216281A (zh) | 2011-10-12 |
US10464912B2 (en) | 2019-11-05 |
US20110275682A1 (en) | 2011-11-10 |
EA023435B1 (ru) | 2016-06-30 |
EA201100245A1 (ru) | 2011-08-30 |
AU2009288037B2 (en) | 2014-08-14 |
GB2476202B (en) | 2012-04-11 |
CY1119752T1 (el) | 2018-06-27 |
PL2326632T3 (pl) | 2017-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA106209C2 (en) | Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid | |
NZ599298A (en) | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin | |
WO2010011926A3 (en) | A novel betaine cocrystal of epalrestat | |
WO2010127195A3 (en) | Treatment of hemoglobin (hbf/hbg) related diseases inhibition of natural antisense transcript to hbf/hbg | |
WO2008108957A3 (en) | Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain | |
WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
MX2013004699A (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos. | |
WO2008100867A3 (en) | Novel inhibitors hepatitis c virus replication | |
WO2008054454A3 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
MX340515B (es) | Terapia antidiabética vasoprotectora y cardioprotectora. | |
NZ593754A (en) | Dpp-iv inhibitors for treatment of diabetes in paediatric patients | |
WO2010114824A8 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
WO2007075695A3 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
WO2009109613A3 (en) | 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | |
WO2009140269A3 (en) | Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis | |
WO2007095615A3 (en) | Use of benzo-heteroaryl sulfamide derivatives for the treatmentof pain | |
MX2012006734A (es) | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas. | |
WO2009109616A3 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40 | |
WO2009109654A8 (en) | 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1 | |
WO2010090494A3 (ko) | 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도 | |
MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
WO2009019708A3 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
WO2011153458A3 (en) | Compositions and methods for inhibition of or treatment of dengue virus infection |